Wall Street analysts’ estimates
Wall Street analysts estimate Thermo Fisher Scientific (TMO) to report 14.1% growth in revenues to ~$23.9 billion in full-year 2018 as compared to $20.9 billion during 2017. EPS is estimated to be $10.99 during 2018 as compared to EPS of $9.49 during 2017. Analysts estimate the net adjusted income to increase to $4.5 billion during 2018 as compared to the net adjusted income of $3.8 billion during 2017.
The above chart compares changes in analysts’ recommendations for Thermo Fisher Scientific since January 2018.
Thermo Fisher Scientific’s stock price has increased by nearly 22.1% in the last 12 months and nearly 24.5% in 2018 year-to-date. Analysts estimate the stock might increase by ~7.0% over the next 12 months. Wall Street analysts have a 12-month target price of $252.86 per share as compared to the last price of $236.43 per share as of September 11, 2018.
As of September 12, 2018, 16 analysts are tracking Thermo Fisher Scientific. Of these, eight analysts recommend a “strong buy,” seven analysts recommend a “buy,” and one analyst recommends a “hold.” The consensus rating for Thermo Fisher Scientific stands at 1.56, which represents a “strong buy” for momentum investors as well as long-term growth investors. Changes in analysts’ estimates and recommendations are based on the changing trends in stock prices and the performance of the company.